Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 312

Posts Tagged ‘immune’

Company Profile for Immune-Onc Therapeutics, Inc.

Posted by fidest press agency su domenica, 24 novembre 2019

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Nano Discovery Inc. Launches a New Blood Test for Cattle Immune Health Testing

Posted by fidest press agency su venerdì, 13 settembre 2019

Nano Discovery Inc. announced today that it has launched a new blood test to the market for cattle immune health testing. Cattle owners and veterinary practitioners can order this test by submitting blood samples to Nano Discovery’s central laboratory, or conduct this test in their local farms and clinics by purchasing testing kits from the company. More information can be found at: A balanced immune system is important for the welfare and productivity of farm animals. Animals with good immune health are less prone to diseases, healthier and more productive. When an animal is infected with bacteria, viruses or other pathogens, the immune system of the animal is activated. An active immune status is a sign of infection in the animal. During pregnancy, the immune system of cows and heifers has to make certain changes to maintain a pregnancy to full term. However, these changes also make pregnant and transition cows and heifers more vulnerable to infectious diseases. By closely monitoring the immune status of cattle herd, farm owners can discover sick animals earlier, identify pregnant animals with underlying reproductive health problems for treatment, identify animals with strong immune system and avoid excessive use of antibiotics on healthy and low risk animals.Despite the critical importance of immune health to the welfare and productivity of agricultural animals including cattle, there was no convenient and cost-effective test in the market that provided farm owners and veterinary practitioners the ability to test and monitor the immune health and status of their cattle easily. Nano Discovery’s new product, the D2Dx™ immunity test, provides the first-ever solution to this unmet need. D2Dx™ immunity test is a simple blood test that detects active immune responses and Th1/Th2 immunity shift associated with infection, pregnancy, and other health conditions that involve the immune system. Research studies conducted by Nano Discovery and its partners have shown that D2Dx™ test can identify cattle with infections; identify dairy cows that are more likely to develop health problems such as ketosis and mastitis following calving; and identify calves with good immune health that can gain more body weight in a feedlot. While D2Dx™ test is not a diagnostic test, the test brings many benefits to cattle owners by helping owners monitor the health of their cattle herd more closely, make informative management decisions, reduce cost and improve productivity.While the current business focus of Nano Discovery is on cattle industry, D2Dx™ immunity test can be applied to the testing of other animals as well. The company is also investigating the use of this test for human infectious diseases, pregnancy loss, autoimmune diseases, and other immune health related problems. D2Dx™ test is based on a nanotechnology platform developed at the University of Central Florida, Orlando, Florida. A PCT patent application is pending on the platform technology and the D2Dx™ immunity test.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Patient immune response could potentially prevent heart failure

Posted by fidest press agency su martedì, 24 aprile 2018

Vienna, Austria. Patients’ own immune response has the potential to prevent the development and progression of heart failure, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology congress.1 The study found antibodies in the plasma and heart muscle of end-stage heart failure patients. “The role of the immune response in the development of heart failure is unknown,” said Patricia van den Hoogen, a PhD student at the University Medical Centre Utrecht / Netherlands Heart Institute in Utrecht, the Netherlands. “We investigated the immune response in patients with end-stage heart failure to see if this might be a new target for treatment.” This study looked at whether patients with end-stage heart failure show signs of inflammation. After a heart attack, inflammation, which is the body’s normal immune response to injury, clears dead cells and other resulting debris. Heart attacks damage the heart muscle and may eventually lead to heart failure, which is a progressive disease. For patients with end-stage heart failure, heart transplantation may be the only treatment option. The study included 20 patients with end-stage heart failure and three healthy controls. Heart failure was caused by ischaemic heart disease (heart attack) in ten patients and by dilated cardiomyopathy in ten patients. The researchers analysed heart tissue and plasma samples to see which antibodies and other immune cells were present. Next they tested the samples with different epitopes to see if they could find the targets of the antibodies.The investigators found increased levels of antibodies in the heart and plasma of end-stage heart failure patients compared to healthy controls .Interestingly, antibody levels were higher in patients with ischaemic heart failure compared to those with dilated heart failure. Levels of other types of immune cells, including T cells, B cells, and macrophages, were significantly higher in the heart tissue of heart failure patients compared to healthy controls. In the plasma, heart failure patients had different types of B cells than healthy controls. Specifically, heart failure patients had more plasma B cells, which produce antibodies, and fewer regulatory B cells, which are immunosuppressive.The epitope screening to identify antibody targets is ongoing. Based on their initial results, the researchers have selected 200 epitopes for follow-up studies. Ms van den Hoogen said: “We observed more inflammation in patients with end-stage heart failure than in healthy people. Heart failure patients had higher levels of antibodies, and more of the cells that produce antibodies. This suggests that the inflammatory response is activated and might play an important role in heart failure.” “These patients were in the final stage of heart failure,” she added. “In future studies we will investigate whether there is an inflammatory response in the early phase of heart failure, and whether the response becomes more pronounced as heart failure worsens.” She concluded: “We now know there is an inflammatory response in patients with end-stage heart failure. This paves the way for creating new therapies to prevent the development or progression of heart failure by targeting the immune response. If we identify the targets of the antibodies through our epitope screening, personalised treatments could be designed.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »